GSK Plc is forecasting an increase in group turnover of 7% to 9% at constant exchange rates this year, but growth is expected to be powered by specialty medicines rather than vaccines. Vaccines for shingles and respiratory syncytial virus (RSV) put in a strong performance earlier this year but slumped in the third quarter following a raft of new regulatory measures.
